Hi Diddy - I don't think you meant to reply to me
Post# of 154804
(Total Views: 603)
Posted On: 05/13/2021 10:59:34 PM
Hi Diddy - I don't think you meant to reply to me with this, but yes, it was an interesting "comparable" proposed by NP.
I don't know if the fact sequence that NP laid out is accurate. Usually he leaves out important stuff. But, I haven't researched it, so I just don't know.
I did a quick google search on Tocilizumab and found the citation below. If the citation from Wikipedia is accurate, then it would seem that Tocilizumab is already an approved FDA drug. So, that would seem to be a different scenario that would apply to Leronlimab.
Thoughts from science folks?
Tocilizumab (INN, trade name Actemra), also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.[1]
I don't know if the fact sequence that NP laid out is accurate. Usually he leaves out important stuff. But, I haven't researched it, so I just don't know.
I did a quick google search on Tocilizumab and found the citation below. If the citation from Wikipedia is accurate, then it would seem that Tocilizumab is already an approved FDA drug. So, that would seem to be a different scenario that would apply to Leronlimab.
Thoughts from science folks?
Tocilizumab (INN, trade name Actemra), also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.[1]
(1)
(0)